Danaher Corporation
Danaher Corporation (NYSE: DHR) is a global science and technology innovator committed to accelerating the power of science and technology to improve human health. The company operates through three primary segments: Biotechnology, Life Sciences, and Diagnostics, each serving distinct but complementary markets within… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Danaher Corporation does
In the company’s own words
Danaher Corporation (NYSE: DHR) is a global science and technology innovator committed to accelerating the power of science and technology to improve human health. The company operates through three primary segments: Biotechnology, Life Sciences, and Diagnostics, each serving distinct but complementary markets within the life sciences and healthcare industries.
The Biotechnology segment, established through the 2015 acquisition of Pall and expanded via the 2020 acquisition of Cytiva, provides equipment, consumables, software and services for advancing biotherapeutic research, development, and manufacturing. The Life Sciences segment encompasses instruments, consumables, services and software for studying DNA, RNA, proteins, metabolites and cells, along with filtration and purification products. This segment was established in 2005 through the acquisition of Leica Microsystems and has grown through subsequent acquisitions including Beckman Coulter, Phenomenex, IDT, Aldevron, and Abcam. The Diagnostics segment offers clinical instruments, consumables, software and services used by hospitals and laboratories for disease diagnosis and treatment decisions, established in 2004 through the acquisition of Radiometer and expanded through acquisitions including Cepheid and HemoCue.
Danaher operates approximately 60,000 employees across roughly 50 countries, with significant presence in North America, Western Europe, and high-growth markets. The company's geographic sales mix reflects North America at 41 percent of total revenue, with the remainder distributed across developed and high-growth international markets. The company markets products under key brands including Cytiva, Pall, Abcam, Aldevron, Beckman Coulter, Cepheid, HemoCue, Leica Microsystems, Molecular Devices, Phenomenex, and Sciex.
The company's operations are unified by the Danaher Business System, a comprehensive management philosophy emphasizing continuous improvement, innovation, and customer focus. Danaher's business model emphasizes recurring revenue through direct sales channels and strategic acquisitions that provide access to specialized technologies and domain expertise. The company generates revenue through both recurring product sales and consumables, as well as nonrecurring equipment and services. Danaher's competitive advantages derive from its portfolio of market-leading brands, integrated technology platforms, global distribution capabilities, and commitment to research and development across its served markets.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- WASHINGTON, DC
- Fiscal year end
- December
- CIK
- 313616
- SIC
- 3823
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Danaher Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Danaher Corporation · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Danaher Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Danaher Corporation’s bonds, as funds hold them
Funds report holding 13 issues of Danaher Corporation’s debt, $423.20M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.59%, maturing 2028 to 2051.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Danaher Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Danaher Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Danaher Corporation's last four quarterly filings that the numbers alone won't show?”